Abstract
Numerous targeted treatments for atopic dermatitis (AD) are currently under investigation in clinical trials. Comparability of the efficacy of new drugs is therefore becoming more and more important. However, this remains challenging given the high intraobserver and interobserver variability of primary endpoints (Flohr, 2011). The use of serological biomarkers may overcome this problem. Recent studies have shown that a combination of serum biomarkers, including TARC, IL-22, and sIL-2R (using a formula called predicted Eczema Area Severity Index [EASI] [p-EASI]), predicts disease severity in patients with AD treated with dupilumab, cyclosporine A, and topical corticosteroids (Bakker et al., 2020; Thijs et al., 2019, 2017).
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
